symbicort turbuhaler 4,5+160 mikrog/dosis inhalationspulver
astrazeneca a/s - budesonid, formoterolfumarat dihydrat - inhalationspulver - 4,5+160 mikrog/dosis
symbicort turbuhaler 4,5+160 mikrog/dosis inhalationspulver
orifarm a/s - budesonid, formoterolfumarat dihydrat - inhalationspulver - 4,5+160 mikrog/dosis
braltus 10 mikrogram inhalationspulver, hård kapsel
teva b.v. - tiotropiumbromid - inhalationspulver, hård kapsel - 10 mikrogram
bufomix easyhaler 4,5+160 mikrog/dosis inhalationspulver
orion corporation - budesonid, formoterolfumarat dihydrat - inhalationspulver - 4,5+160 mikrog/dosis
bufomix easyhaler 4,5+160 mikrog/dosis inhalationspulver
orifarm a/s - budesonid, formoterolfumarat dihydrat - inhalationspulver - 4,5+160 mikrog/dosis
bufomix easyhaler 4,5+160 mikrog/dosis inhalationspulver
2care4 aps - budesonid, formoterolfumarat dihydrat - inhalationspulver - 4,5+160 mikrog/dosis
symbicort turbuhaler 4,5+160 mikrog/dosis inhalationspulver
abacus medicine a/s - budesonid, formoterolfumarat dihydrat - inhalationspulver - 4,5+160 mikrog/dosis
bufoler easyhaler 4,5+160 mikrog/dosis inhalationspulver
orifarm a/s - budesonid, formoterolfumarat dihydrat - inhalationspulver - 4,5+160 mikrog/dosis
bufomix easyhaler 4,5+160 mikrog/dosis inhalationspulver
paranova danmark a/s - budesonid, formoterolfumarat dihydrat - inhalationspulver - 4,5+160 mikrog/dosis
biresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - medicin for obstruktiv sygdomme, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).